A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)

被引：0

作者：

Beeram, M.

Krop, I.

Modi, S.

Tolcher, A.

Rabbee, N.

Girish, S.

Tibbitts, J.

Holden, S.

Lutzker, S.

Burris, H.

机构：

[1] Inst Drug Dev, San Antonio, TX USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[4] Genentech Inc, San Francisco, CA 94080 USA

[5] Sarah Cannon Canc Ctr, Nashville, TN USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1042

引用

页数：1

共 50 条

[31] A Mechanistic Pharmacokinetic Model Elucidating the Disposition of Trastuzumab Emtansine (T-DM1), an Antibody-Drug Conjugate (ADC) for Treatment of Metastatic Breast Cancer
Bender, Brendan
Leipold, Douglas D.
Xu, Keyang
Shen, Ben-Quan
Tibbitts, Jay
Friberg, Lena E.
AAPS JOURNAL, 2014, 16 (05): : 994 - 1008
[32] Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
Chunze Li
Bei Wang
Dan Lu
Jin Y. Jin
Yuying Gao
Kiyoshi Matsunaga
Yuriko Igawa
Ihsan Nijem
Michael Lu
Alexander Strasak
Nataliya Chernyukhin
Sandhya Girish
Cancer Chemotherapy and Pharmacology, 2016, 78 : 547 - 558
[33] Population Pharmacokinetics of Trastuzumab-DM1, a First-in-Class HER2 Antibody-Drug Conjugate Given Every 3 Weeks (q3w) and Weekly (qw) to Patients with HER2-Positive Metastatic Breast Cancer (MBC)
LoRusso, P.
Girish, S.
Burris, H. A.
Beeram, M.
Vukelja, S.
Modi, S.
Yi, J-H
Wang, B.
Saad, O.
Gupta, M.
CANCER RESEARCH, 2009, 69 (24) : 798S - 799S
[34] Tucatinib potentiates the activity of the antibody-drug conjugate T-DM1 in preclinical models of HER2-positive breast cancer
Kulukian, Anita
Taylor, Janelle
Jain, Nishi
Olson, Devra
Zaval, Margo
Thurman, Robert
Hengel, Shawna
Farr, Lauren
Pires, Thomas
Peterson, Scott R.
CANCER RESEARCH, 2021, 81 (04)
[35] A phase 1b study of S-1 combined with trastuzumab emtansine (T-DM1) for HER2 positive metastatic breast cancer
Kojima, Yasuyuki
Yoshie, Reiko
Kawamoto, Hisanori
Shimo, Arata
Uejima, Tomoko
Iwatani, Tsuguo
Motoyoshi, Ai
Haku, Ei
Kanemaki, Yoshihide
Tsugawa, Koichiro
ANNALS OF ONCOLOGY, 2018, 29
[36] T-DM1 for HER2-positive metastatic breast cancer
Yaqub, Farhat
LANCET ONCOLOGY, 2013, 14 (03): : E94 - E94
[37] Lapatinib-based therapies after pertuzumab and/or T-DM1 for HER2+metastatic breast cancer patients
Frezzini, S.
Giarratano, T.
Dieci, M. V.
Giorgi, C. A.
Griguolo, G.
Vernaci, G.
Menichetti, A.
Mantiero, M.
Tasca, G.
Faggioni, G.
Falci, C.
Miglietta, F.
Mioranza, E.
Angelini, S.
Ghiotto, C.
Conte, P.
Guarneri, V.
CANCER RESEARCH, 2019, 79 (04)
[38] Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer
Boyraz, Baris
Sendur, Mehmet A. N.
Aksoy, Sercan
Babacan, Taner
Roach, Emir C.
Kizilarslanoglu, Muhammet C.
Petekkaya, Ibrahim
Altundag, Kadri
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (04) : 405 - 414
[39] Phase I study of alpelisib and T-DM1 in trastuzumab-refractory HER2-positive metastatic breast cancer.
Jain, Sarika
Nye, Lauren Elizabeth
Santa-Maria, Cesar Augusto
Garrett, Hannah
Dammrich, Ellen
Williams, Amanda
Bontemps, Lauren
Flaum, Lisa E.
Giles, Francis J.
Gradishar, William John
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[40] T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2
Roberta Nicoletti
Salvatore Lopez
Stefania Bellone
Emiliano Cocco
Carlton L. Schwab
Jonathan D. Black
Floriana Centritto
Liancheng Zhu
Elena Bonazzoli
Natalia Buza
Pei Hui
Delia Mezzanzanica
Silvana Canevari
Peter E. Schwartz
Thomas J. Rutherford
Alessandro D. Santin
Clinical & Experimental Metastasis, 2015, 32 : 29 - 38

← 1 2 3 4 5 →